Apar Ganti, MD, University of Nebraska Medical Center

Articles by Apar Ganti, MD, University of Nebraska Medical Center

Q & A and Final Thoughts

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Unmet Needs and Challenges in Treating R/R SCLC

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Role of Newer Agents in the Treatment & Patient Selection

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Data on FDA Approved Therapy for Relapsed/Refractory SCLC

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Use of I/O Regimen in Relapsed/Refractory SCLC

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Advice on Toxicity Management for SCLC Therapy

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Personal Approach in Treatment Compared to Clinical Trials

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Recent Progress in the Treatment of SCLC

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Introduction and Identifying Predictive Biomarkers

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Latest Updated Articles

Role of Newer Agents in the Treatment & Patient Selection
August 20th 2020
Advice on Toxicity Management for SCLC Therapy
August 20th 2020
$Data on FDA Approved Therapy for Relapsed/Refractory SCLC$
Data on FDA Approved Therapy for Relapsed/Refractory SCLC
August 20th 2020
Q & A and Final Thoughts
August 20th 2020
Recent Progress in the Treatment of SCLC
August 20th 2020
$Use of I/O Regimen in Relapsed/Refractory SCLC$
Use of I/O Regimen in Relapsed/Refractory SCLC
August 20th 2020

Trending on OncLive

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

VIR-5500 Receives FDA Fast Track Designation in mCRPC

The OncFive: Top Oncology Articles for the Week of 10/4/2026

FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer

Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma